Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck & Co. completes acquisition of NovaCardia
This acquisition adds rolofylline, NovaCardia's investigational Phase III compound for acute heart failure, to Merck's pipeline. Merck has acquired all the outstanding equity of NovaCardia for a total
This acquisition adds rolofylline, NovaCardia's investigational Phase III compound for acute heart failure, to Merck's pipeline. Merck has acquired all the outstanding equity of NovaCardia for a total
Philip Dean, CSO at De Novo, said: “We are very pleased to be working with Achaogen – a leader in the fight against drug-resistant bacteria.” Phillip Patten, senior
The randomized multinational study was conducted by Merck KGaA, and enrolled patients with stage IIIB or stage IV non-small cell lung cancer who had not previously received chemotherapy.
The Phase II trial is a single-blinded, placebo controlled, three-way crossover and randomized in up to 60 patients, with the endpoint of assessing the efficacy of TPM/Insulin in
Two of these trials will investigate the use of subcutaneous methylnaltrexone for treating opioid-induced constipation in patients outside of the palliative care population. The third trial will investigate
The Federal Trade Commission and the US Department of Justice, Antitrust Division have granted early termination of the Hart-Scott-Rodino waiting period for the previously announced merger agreement between
The order issued by the US Court of Appeals for the Federal Circuit, which has nationwide jurisdiction in various subject areas that include patents, requires Teva to submit
Jack Armstrong, president and CEO said: “Genaera is privileged and honored to work with this prestigious group of nationally and internationally recognized experts to guide our trodusquemine (MSI-1436)
The data were collected as part of the company's ongoing pivotal trial for SinuNase, an intranasal formulation of the antifungal amphotericin B 0.01% suspension. In order to be
Under the terms of the settlement, the license agreement will remain in full force and effect until March 31, 2008. Furthermore, Pohl-Boskamp has agreed to pay Stellar E200,000,